በTexas ለሆጅኪን ሊምፎማ የሚደረጉ ክሊኒካዊ ጥናቶች
ለሆጅኪን ሊምፎማ የሚደረጉ 15 ጥናቶች በTexas ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በTexas ውስጥ ያሉ ከተሞች
Official study text (English)
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ12 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT06176690CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ12 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT02917083Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ ከ0 እስከ 38 · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06131801A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
- M D Anderson Cancer Center, Houston
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ሴፕቴ 2026 · NCT05615636Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- Sarah Cannon Research Institute at St. David's South Austin, Austin
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ18 እስከ 100 · ሁሉም ጾታዎች · የተሻሻለው በ15 ሴፕቴ 2026 · NCT05798897AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Research Site, Houston
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT06137144Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
- The University of Texas M. D. Anderson Cancer Center, Houston
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT07444632Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
- UT MD Anderson, Houston
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ2 እስከ 21 · ሁሉም ጾታዎች · የተሻሻለው በ31 ኦገስ 2026 · NCT07551583Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- M D Anderson Cancer Center, Houston
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ ከ12 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ7 ኦገስ 2026 · NCT05092451Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ15 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ30 ጁላይ 2026 · NCT02727803A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
- Zachary & Elizabeth Fisher Bone Marrow Transplant Program (Brooke Army Medical Center), Fort Sam Houston
- እና 5 ተጨማሪ
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ6 ጁላይ 2026 · NCT01351545EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
- Harris Health System - Ben Taub General Hospital/Smith Clinic, Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
- እና 1 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 1
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ25 ጁን 2026 · NCT04664179A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
- MD Anderson Cancer Center, Houston
ተሳታዮችን በመፈለግ ላይደረጃ 2ጤናማ ተሳታዮች ይቀበላሉ
እድሜ 1 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ሜይ 2026 · NCT05355051Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
ተሳታዮችን በመፈለግ ላይደረጃ 1
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ2 ማርች 2026 · NCT01555892Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- University of Texas, Southwestern, Dallas
- Cook Children's Hospital, Fort Worth
- Texas Children's Hospital/Baylor College of Medicine, Houston
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ1 እስከ 21 · ሁሉም ጾታዎች · የተሻሻለው በ6 ዲሴም 2024 · NCT05476770ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።